IDH2 mutations did not show any impact on survival in GBM cases as depicted by Yan et al. [10], but interestingly showed better survival in astrocytoma cases (51.5 vs wild-type 21.8 months, log-rank p = 0.02). This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).